CX1942 is an Ampakine that has been specifically designed as an injectable drug product for the treatment of respiratory depression. As an intravenous delivery it is rapid acting. It has also been tested in animal studies in a subcutaneous and intramuscular route of administration.
It is highly soluble in water and physiological saline, and in rodent tests of opiate-induced respiratory depression, is several times more potent than CX1739, and, with intravenous administration, is highly effective in a ‘rescue’ paradigm where the test animal has already stopped breathing due to an opioid overdose. This potentially makes CX1942 ideal for hospital use in the post-surgical setting when patients are typically in the most pain, and the risk of respiratory depression due to opioid painkillers is high. Post-surgical in-patients are often allowed to use patient-controlled analgesia (PCA) soon after surgery, where the patient self-administers controlled intravenous doses of morphine or other potent opioid painkillers. Even though safeguards in the PCA device limits total dose and time interval between doses, sensitivity to opioids, as well as other parameters such as rate of metabolism, and other factors, can vary among individuals, and lead to an overdose situation and respiratory depression or respiratory arrest, which can be fatal. Use of CX1942 may also permit higher doses of these painkillers to achieve better pain management while reducing the risk of undesirable respiratory depression.
In the near future, RespireRx plans to initiate formal toxicology and safety pharmacology studies necessary to support an IND-type regulatory dossier required for Phase 1 studies with CX1942.